Hadassah

Hadassah-Developed Autoimmune Disease Drug Proves Safe in Phase I Clinical Trial

Thursday, Aug 6 2015

A drug developed at the Hadassah Medical Organization to help modulate the effects of autoimmune diseases such as rheumatoid arthritis has proven safe in a Phase I clinical trial at Hadassah. Manufactured by Protalix BioTherapeutics of Carmiel, Israel, the drug, PRX-106, proved to activate T cells, which have a central role in maintaining a well-functioning immune system.

"The results are very exciting and encouraging,” reports Prof. Yaron Ilan of Hadassah’s Internal Medicine Department A and a specialist in immunology and liver disease. “PRX-106 has the potential to be an effective agent for numerous immune-mediated disorders."

This Phase I trial tested the safety and tolerability of PRX-106 in healthy volunteers. With three separate cohorts receiving different doses of the protein compound for five consecutive days, the results demonstrated that oral administration of PRX-106 is safe and well tolerated in all three doses. In addition, researchers observed that PRX-106 triggered the action of various subsets of T cells, some of which are correlated with an anti-inflammatory response.

Preclinical studies with PRX-106 proved to alleviate both immune-mediated hepatitis and colitis in a mouse model, enhancing serum levels of regulatory T-cells and significantly improving clinical arthritis parameters, such as joint inflammation, swelling, and tissue degradation.

PRX-106 uses plant cells as a natural capsule for this protein compound. Protaliz anticipates that it will initiate the next phase of clinical trials with patients at the end of the year.

Comments

From: Penny Ellis on December 5, 2017
Will this drug help people with Crihn's Disease?
From: Gila on September 10, 2015
Would this drug also be one that could be effective in treating Crohn's Disease patients? As is now true of the RA drugs that work with T cells and the autoimmune system? Which I now inject....the oral/pill form sounds much more tolerable considering my Dr. says I will need to continue my therapy for life!
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Tuesday, Aug 13 2019

Alzheimer’s Further Illuminated at Hadassah with New Exclusive Imaging Agent

The Hadassah Medical Organization, through its subsidiary SRY, has contracted to be the sole Israeli agent for General Electric to produce Vizamy, the company’s new radioactive imaging agent to detect, at an early stage, amyloid plaque, which has been linked to the development of Alzheimer’s disease.

READ MORE ›
alt_text

Friday, Aug 2 2019

New Thyroid Eye Disease Clinic at Hadassah Brings Integrated Care to New Mom

Miriam, 34, had just given birth to her third child, and, unlike the joy she felt after her first two births, she felt awful.

READ MORE ›
alt_text

Friday, Aug 2 2019

Eloxx Pharmaceuticals Announces New Drug Application for Clinical Trial in Cystic Fibrosis Patients

Professor Eitan Kerem, head of the Division of Pediatrics at the Hadassah Medical Organization, will serve as the Global Lead Investigator for this clinical trial.

READ MORE ›
alt_text

Wednesday, Jul 31 2019

Skin Cancer Treatment Enhanced in New Center for Dermatologic Surgery

Thanks to a donation by the Israeli businessman and philanthropist Morris Kahn, a major supporter of the Israeli moon spacecraft “Beresheet,” Hadassah Hospital Ein Kerem has just opened the new Center for Dermatologic Surgery, which offers Mohs surgery for patients with common types of skin cancer.

READ MORE ›
SUPPORT HADASSAH HOSPITALS

Learn more about the Hadassah Medical Organization.

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More